about
Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence[Low dose melphalan therapy was effective in an elderly patient with MDS-AML].[Reliability of low platelet counts--comparison of microscopic counts with automated hematology analyzer XE-2100].Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan.Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure.[Discussion meeting on immune thrombocytopenia].The Repeated Administration of Resveratrol Has Measurable Effects on Circulating T-Cell Subsets in Humans.Genetic variants of human granzyme B predict transplant outcomes after HLA matched unrelated bone marrow transplantation for myeloid malignancies.A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation.Resveratrol induces cell cycle arrest and apoptosis in malignant NK cells via JAK2/STAT3 pathway inhibitionParaptosis cell death induction by the thiamine analog benfotiamine in leukemia cellsEfficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy.Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy.Light Chain Deposition Disease Diagnosed with Laser Micro-dissection, Liquid Chromatography, and Tandem Mass Spectrometry of Nodular Glomerular Lesions.Primary tracheal lymphoma: case report and literature review.NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignanciesA functional polymorphism in the NKG2D gene modulates NK-cell cytotoxicity and is associated with susceptibility to Human Papilloma Virus-related cancers.Role of non-HLA gene polymorphisms in graft-versus-host disease.Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia.Overexpression of salivary-type amylase reduces the sensitivity to bortezomib in multiple myeloma cells.Successful Secondary Umbilical Cord Blood Transplantation for Graft Failure in Acute Myelogenous Leukemia, Treated with Modified One-Day Conditioning Regimen, and Graft-Versus-Host Disease Prophylaxis Consisting of Mycophenolate and Tacrolimus.Ataxia-telangiectasia mutated kinase-mediated upregulation of NKG2D ligands on leukemia cells by resveratrol results in enhanced natural killer cell susceptibility.Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia.Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide.Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Nationwide Survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for HematAcute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT.Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first CR.Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission.The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation.Toll-like receptor genetic variations in bone marrow transplantation.Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia.Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab.Outcomes of allogeneic hematopoietic cell transplantation in patients with biphenotypic acute leukemia.Livedoid vasculopathy and popliteal artery occlusion in a patient with protein S deficiency.Toll-like receptor 1 variation increases the risk of transplant-related mortality in hematologic malignancies.Effect of Granulocyte Colony-Stimulating Factor-Combined Conditioning in Cord Blood Transplantation for Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia: A Retrospective Study in Japan.A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation.Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement.Fibroblast Growth Factor-2 facilitates the growth and chemo-resistance of leukemia cells in the bone marrow by modulating osteoblast functions.Successful hyperbaric oxygen therapy for refractory BK virus-associated hemorrhagic cystitis after cord blood transplantation.
P50
Q26745552-12B8C7F6-9399-4A4F-9BD0-ED6486C90D4DQ33337914-F6779D05-D31C-4411-A4FB-33333B254961Q33368991-D0E53E91-58E6-4960-ACFB-C6602B145769Q33394786-2E81D4F3-0F0F-4A4A-8293-56B85E77D531Q33405829-E8BB0A53-726F-426B-9A82-92BAFCA8A0F1Q33417288-E1D510CE-01A2-4815-840F-ACB525B86F30Q33701615-C332ECBC-3A25-4442-B06E-7CCEF31068D3Q34008970-B0AB11E9-6553-44B2-8C34-73BB60DA3B43Q34058468-40B14CD2-DA8C-44A4-A0C1-6E0636328BDEQ34571639-64C5F945-CF79-47E6-B46F-425A1A951769Q35596628-791883E8-2E99-49A6-9076-228AA2337698Q35859239-714396A5-2283-47DB-8BAD-0D42E94FFABDQ36025319-9A9674C1-65E5-4630-85AC-B5339EA4C660Q36239063-C8F9F011-28B1-48E9-A4BE-968CFEAF6E46Q36317962-4CA3F9D8-D9C8-4704-AA38-A2D1C3D8F48BQ37369943-1403E9F2-85BA-49C7-AFEE-7338D3FC29ABQ37519488-F07DC290-926F-4E9C-A059-02D01959E5A4Q38129337-7E499AAD-1115-414C-A4CF-2154AABA3870Q38770125-FBEE0572-C101-4D0E-BED2-A562C4865D52Q38837700-406DA584-15A4-4A32-B16F-EE985D3894F0Q38951063-4CA00165-211F-451C-892A-3FDB05CF1734Q39187764-F468ED75-72B3-46FD-B973-E2CB5F2CEDFFQ39192183-E5824795-73BB-45E6-9F5A-C54AFBAA4FA5Q39323997-F569A3FD-3C2C-47F1-A8B9-047EDE9DAA28Q39352795-06EA3174-F0DF-4370-85DC-97020E6B82ECQ39722840-7C1659DF-429E-47AB-A146-759119A88EFDQ40064058-979E4289-56F3-493D-B231-709DD4FF0505Q40199108-7763049E-665B-4183-A588-CCBD657077EAQ40208593-7B6C2845-5A73-44DA-A391-8A475FFF9B2AQ40209654-8933FA6E-4745-4A6E-9746-F2515AC4DF48Q40216218-FF0C3A01-45BA-4819-ADF2-4113456C0732Q40338040-64FA66F0-CDE9-4551-B551-3D83A73565E1Q40394913-D7333376-782C-4030-922A-582313710E70Q40489272-85466D5F-AE01-4ABB-A098-A620FBF520E3Q40628153-360FD6AC-CD01-405C-B107-5593D54912B9Q40927612-EB2A5541-A31E-4ED8-9767-210763ACD269Q41070167-8D31214A-4FE1-4B84-A4DA-0A7C3FFD86D3Q41750234-9810E410-43D4-45DC-A8B2-EA678947DC7EQ41849671-B14998AC-BA3E-461D-B3E3-D9C5CECE9C16Q42205193-2F7A3BF4-560C-4EFF-BCBE-38D4433E60F6
P50
description
researcher ORCID ID = 0000-0002-1822-9976
@en
wetenschapper
@nl
name
Akiyoshi Takami
@ast
Akiyoshi Takami
@en
Akiyoshi Takami
@es
Akiyoshi Takami
@nl
type
label
Akiyoshi Takami
@ast
Akiyoshi Takami
@en
Akiyoshi Takami
@es
Akiyoshi Takami
@nl
prefLabel
Akiyoshi Takami
@ast
Akiyoshi Takami
@en
Akiyoshi Takami
@es
Akiyoshi Takami
@nl
P108
P31
P496
0000-0002-1822-9976